MIRM
Mirum Pharmaceuticals, Inc.
Stock
$82.93−0.99 (−1.18%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $618M | $521M | $337M | $186M | $77M | $19M | $0 |
| R&D | $283M | $186M | $141M | $103M | $107M | $131M | $82M |
| SG&A | $314M | $257M | $202M | $146M | $89M | $59M | — |
| Operating income | −$834M | −$22M | −$88M | −$109M | −$131M | −$173M | −$104M |
| Non-operating income | −$24M | $709K | $694K | −$53M | −$11M | $89M | $1.0M |
| Pretax income | −$858M | −$21M | −$87M | −$162M | −$142M | −$84M | −$103M |
| Taxes | $2.7M | $1.9M | $1.0M | $991K | −$6.4M | $37K | $6K |
| Net income | −$860M | −$23M | −$88M | −$163M | −$136M | −$84M | −$103M |
| Diluted EPS | −$14.57 | −$0.47 | −$1.85 | −$4.00 | −$4.02 | −$2.77 | −$4.09 |
| Diluted shares | — | 50.2M | 47.5M | 40.9M | 34.0M | 30.3M | 25.3M |
| Revenue growth | — | +54.7% | +80.8% | +141.8% | +302.7% | — | — |
| Operating margin | −134.9% | −4.2% | −26.0% | −58.6% | −170.3% | −906.1% | — |
| Net margin | −139.2% | −4.5% | −26.1% | −87.7% | −176.0% | −438.9% | — |